ARTICLE | Financial News
Akeso raises $45M in series B
August 28, 2017 10:13 PM UTC
Akeso Biopharma Inc. (Zhongshan, China) raised RMB300 million ($45.2 million) in a series B round led by Shenzhen GTJA Investment Group. Existing investors Shenzhen Capital, Qianhai Parent Fund and Qianhai TRI Wise Capital participated.
In 2015, Akeso granted Merck & Co. Inc. (NYSE:MRK) rights to its preclinical immune checkpoint blocking antibody AK-107 for an undisclosed upfront payment and up to $200 million in milestones...
BCIQ Company Profiles